A Phase 1 interventional study of PF-06700841 oral solution/suspension and Placebo in Plaque Psoriasis, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.
Among the 57 studies in Psoriasis by Pfizer, this one is the 24th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2014, is one of 10 in phase 1, and was the 48th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 42 interventional studies, 458 across the 15 observational. Of the 56 that completed or were terminated, 46 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Psoriasis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key Inclusion Criteria for Healthy Subject Cohorts:
Key Inclusion Criteria for Psoriasis Subject Cohorts:
Exclusion Criteria:
Key Exclusion Criteria for Healthy Subject Cohorts:
Key Exclusion Criteria for Psoriasis Subject Cohorts:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-06700841 oral solution/suspension
Drug: PF-06700841 tablet
Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
Other: Placebo
Drug page: PF-06700841
Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
Matching placebo given during the single ascending and multiple dose periods
PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1
Time frame: Baseline, 24 hours post-dose on Day 1
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10
Time frame: Baseline, 16 hours post-dose on Day 10
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28
Time frame: Baseline, 16 hours post-dose on Day 28
Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1
Time frame: Baseline, 24 hours post-dose on Day 1
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10
Time frame: Baseline, 16 hours post-dose on Day 10
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28
Time frame: Baseline, 16 hours post-dose on Day 28
Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1
Time frame: Baseline, 24 hours post-dose on Day 1
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10
Time frame: Baseline, 16 hours post-dose on Day 10
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28
Time frame: Baseline, 16 hours post-dose on Day 28
Number of Participants With Change From Baseline in Physical Examinations
Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1
Time frame: Baseline, 24 hours post-dose on Day 1
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10
Time frame: Baseline, 16 hours post-dose on Day 10
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28
Time frame: Baseline, 16 hours post-dose on Day 28
Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1
Time frame: Baseline, 24 hours post-dose on Day 1
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10
Time frame: Baseline, 16 hours post-dose on Day 10
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28
Time frame: Baseline, 16 hours post-dose on Day 28
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.
Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Number of Adverse Events (AEs) According to Severity
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.
Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Number of Participants With Laboratory Abnormalities
Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(\<) 0.8\*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: \<0.9\*LLN,\>1.1\*upper limit of normal (ULN); platelets: \<0.5\*LLN,\>1.75\*ULN, white blood cell count: \<0.6\*LLN, \>1.5\*ULN; lymphocytes, total neutrophils: \<0.8\*LLN, \>1.2\*ULN; eosinophils, basophils, monocytes: \>1.2\*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: \>1.1\*ULN; liver function: bilirubin: \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\*ULN; protein, albumin: \<0.8\*LLN\>\</0\>1.2\*ULN; renal function:blood urea nitrogen,creatinine: \>1.3\*ULN; uric acid: \>1.2\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\*LLN,\>1.1\*ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\*LLN,\>1.5\*ULN)
Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1
Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.
Time frame: Baseline, 24 hours post-dose on Day 1
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10
Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.
Time frame: Baseline, 16 hours post-dose on Day 10
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28
Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.
Time frame: Baseline, 16 hours post-dose on Day 28
Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841
Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841
Time frame: SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841
Time frame: SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841
Time frame: Pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841
Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.
Time frame: MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841
Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841
Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.
Time frame: SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.
Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841
Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.
Time frame: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841
Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.
Time frame: SAD: pre--dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre--dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841
MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.
Time frame: SAD: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.
Time frame: SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841
PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC\[tau\]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.
Time frame: MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28
Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)
Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.
Time frame: 0-24 hour on Day 10
Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)
Aetau% was calculated as: 100\*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.
Time frame: 0-24 hours on Day 10
Multiple Ascending Dose (MAD) Cohort: Renal Clearance
Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.
Time frame: 0-24 hours on Day 10
Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline
Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.
Time frame: Baseline
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28
Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.
Time frame: Baseline, Day 2, 5, 10, 11, 28
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56
Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.
Time frame: Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56
Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline
Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.
Time frame: Baseline
Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28
Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.
Time frame: Baseline, Day 2, 5, 10, 11, 28
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56
Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.
Time frame: Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56
Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8
Time frame: Baseline, Day 2, 5, 8
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28
Time frame: Baseline, Day 4, 8, 10, 11, 14, 28
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56
Time frame: Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56
Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8
Time frame: Baseline, Day 2, 5, 8
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28
Time frame: Baseline, Day 4, 8, 10, 11, 14, 28
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56
Time frame: Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56
| Milestone | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted | PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed | PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted | PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed | PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted | PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 6 | 8 | 8 | 13 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 6 | 6 | 6 | 5 | 8 | 8 | 12 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted | PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed | PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted | PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed | PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted | PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 6 | 5 | 8 | 8 | 12 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 0 | 0 | 5 | 4 | 6 | 6 | 9 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted | PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed | PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted | PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed | PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted | PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 5 | 4 | 6 | 6 | 9 | 9 | 14 | 7 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 0 | 0 | 5 | 3 | 6 | 4 | 9 | 7 | 6 | 4 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 2 | 8 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted | PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed | PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted | PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed | PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted | PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 0 | 9 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 0 | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted | PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed | PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted | PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed | PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted | PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 0 | 0 | 0 | 0 | 4 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| millimeter of mercury (mmHg) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Supine Systolic Blood Pressure (SBP): Baseline | 114.2 ± 11.97 | 110.6 ± 6.70 | 108.7 ± 7.76 | 102.8 ± 6.62 | 117.8 ± 9.54 | 112.4 ± 12.26 | 115.3 ± 5.99 |
| Supine SBP: Change at Day 1 | -2.6 ± 6.40 | -8.1 ± 9.32 | 1.0 ± 8.17 | 9.5 ± 5.96 | -1.5 ± 4.64 | 2.1 ± 11.28 | -5.3 ± 7.91 |
| Supine Diastolic blood pressure (DBP): Baseline | 64.0 ± 8.55 | 67.0 ± 8.77 | 66.2 ± 8.42 | 58.7 ± 8.19 | 70.3 ± 7.39 | 66.9 ± 8.98 | 70.5 ± 5.88 |
| Supine DBP: Change at Day 1 | -1.1 ± 7.44 | -5.3 ± 9.05 | 2.2 ± 9.56 | 4.7 ± 715 | 2.5 ± 8.83 | -0.1 ± 8.36 | -2.3 ± 6.14 |
| mmHg | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Supine SBP: Baseline (n=9,2,5,4,6,5,6) | 112.2 ± 9.78 | 106.5 ± 3.54 | 103.6 ± 7.64 | 110.3 ± 5.19 | 111.5 ± 13.35 | 108.6 ± 18.45 | 115.8 ± 8.66 |
| Supine SBP: Change at Day 10 (n=9,2,5,3,6,4,4) | 4.0 ± 9.12 | 12.5 ± 2.12 | -0.2 ± 7.69 | 8.7 ± 10.69 | 7.7 ± 12.97 | -3.5 ± 8.89 | -5.3 ± 4.86 |
| Supine DBP: Baseline (n=9,2,5,4,6,5,6) | 60.3 ± 4.15 | 61.5 ± 7.78 | 56.2 ± 4.02 | 65.5 ± 3.70 | 68.8 ± 9.06 | 59.2 ± 16.80 | 66.2 ± 8.06 |
| Supine DBP: Change at Day 10 (n=9,2,5,3,6,4,4) | 4.2 ± 7.26 | 6.0 ± 4.24 | 2.2 ± 6.76 | 5.7 ± 1.53 | 3.2 ± 9.62 | -4.3 ± 9.14 | 2.0 ± 5.48 |
| mmHg | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Supine SBP: Baseline (n =9, 14, 7) | 115.0 ± 13.21 | 120.1 ± 10.91 | 112.9 ± 8.11 |
| Supine SBP: Change at Day 28 (n =8, 7, 5) | -5.3 ± 11.87 | -8.9 ± 9.94 | 1.0 ± 11.94 |
| Supine DBP: Baseline (n =9, 14, 7) | 67.8 ± 7.93 | 69.9 ± 7.94 | 66.6 ± 7.55 |
| Supine DBP: Change at Day 28 (n =8, 7, 5) | -3.9 ± 5.51 | -7.0 ± 6.00 | -0.8 ± 16.96 |
| beats per minute (bpm) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline | 57.5 ± 6.36 | 68.6 ± 13.81 | 67.2 ± 9.66 | 56.0 ± 8.05 | 67.3 ± 9.24 | 55.8 ± 11.77 | 57.8 ± 6.54 |
| Change at Day 1 | 1.0 ± 3.42 | 6.1 ± 7.58 | 2.5 ± 6.28 | 3.0 ± 8.10 | 0.7 ± 5.54 | -1.1 ± 3.94 | 2.6 ± 6.39 |
| bpm | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =9,2,5,4,6,5,6) | 59.3 ± 12.58 | 59.0 ± 1.41 | 55.8 ± 7.36 | 60.8 ± 4.99 | 61.5 ± 7.50 | 66.0 ± 9.43 | 60.5 ± 9.61 |
| Change at Week 10 (n =9,2,5,3,6,4,4,) | -2.3 ± 12.21 | -0.5 ± 0.71 | -1.6 ± 5.18 | -4.0 ± 7.21 | -6.3 ± 8.24 | -2.5 ± 4.43 | -1.0 ± 6.38 |
| bpm | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n =9, 14, 7) | 61.8 ± 8.07 | 61.4 ± 9.52 | 64.9 ± 6.04 |
| Change at Week 28 (n =8, 7, 5) | -1.9 ± 5.38 | -5.3 ± 7.41 | -3.0 ± 3.39 |
| degree celsius | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline | 36.79 ± 0.155 | 36.83 ± 0.359 | 36.65 ± 0.187 | 36.82 ± 0.194 | 36.80 ± 0.141 | 36.69 ± 0.164 | 36.63 ± 0.149 |
| Change at Day 1 | 0.05 ± 0.151 | -0.11 ± 0.418 | 0.35 ± 0.281 | 0.05 ± 0.235 | 0.07 ± 0.103 | -0.03 ± 0.238 | 0.05 ± 0.177 |
| degree celsius | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =9, 2, 5, 4, 6, 5, 6) | 36.71 ± 0.136 | 36.70 ± 0.141 | 36.76 ± 0.182 | 36.68 ± 0.126 | 36.83 ± 0.163 | 36.76 ± 0.167 | 36.75 ± 0.235 |
| Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4) | 0.08 ± 0.228 | 0.05 ± 0.071 | -0.22 ± 0.164 | -0.10 ± 0.100 | -0.22 ± 0.214 | -0.17 ± 0.206 | 0.05 ± 0.208 |
| degrees celsius | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n = 9, 14, 7) | 36.74 ± 0.151 | 36.67 ± 0.213 | 36.80 ± 0.277 |
| Change at Week 28 (n= 8, 7, 5) | 0.01 ± 0.223 | -0.04 ± 0.369 | -0.20 ± 0.300 |
Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
| participants | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Change From Baseline in Physical Examinations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| millisecond (msec) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| PR Interval: Baseline | 175.7 ± 14.52 | 149.7 ± 18.62 | 163.1 ± 13.58 | 168.2 ± 14.63 | 163.6 ± 19.37 | 175.8 ± 18.86 | 165.9 ± 7.65 |
| PR Interval: Change at Day 1 | -0.9 ± 6.78 | 6.7 ± 8.12 | -2.4 ± 6.65 | 2.2 ± 5.45 | -2.1 ± 5.95 | 3.3 ± 5.62 | 0.5 ± 7.54 |
| QRS Complex: Baseline | 97.7 ± 15.40 | 92.9 ± 9.30 | 97.4 ± 10.43 | 102.9 ± 8.74 | 99.8 ± 14.61 | 101.7 ± 6.87 | 92.0 ± 5.81 |
| QRS Complex: Change at Day 1 | -3.1 ± 12.73 | -1.5 ± 5.98 | -2.2 ± 4.06 | -1.7 ± 3.55 | -2.9 ± 3.45 | -2.0 ± 5.19 | 1.7 ± 2.33 |
| QT Interval: Baseline | 408.4 ± 21.42 | 374.0 ± 21.81 | 384.3 ± 26.20 | 404.2 ± 19.89 | 387.5 ± 12.0 | 421.3 ± 29.94 | 407.1 ± 20.71 |
| QT Interval: Change at Day 1 | -5.9 ± 10.41 | -3.8 ± 10.21 | -3.1 ± 9.43 | -8.2 ± 9.25 | -0.8 ± 4.56 | -0.8 ± 11.61 | -3.3 ± 14.78 |
| QTC Interval: Baseline | 397.7 ± 16.51 | 390.9 ± 20.95 | 400.6 ± 11.90 | 392.2 ± 13.42 | 402.7 ± 20.69 | 400.0 ± 7.60 | 402.7 ± 14.10 |
| QTC Interval: Change at Day 1 | -0.2 ± 9.24 | -2.3 ± 5.45 | -1.9 ± 7.61 | 2.4 ± 9.42 | -4.6 ± 4.41 | 4.2 ± 7.75 | 3.2 ± 5.76 |
| msec | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| PR Interval: Baseline (n =9,2,5,4,6,5,6) | 176.9 ± 16.31 | 180.0 ± 1.41 | 167.6 ± 10.69 | 169.0 ± 22.38 | 168.5 ± 18.79 | 171.6 ± 14.77 | 168.0 ± 6.66 |
| PR Interval: Change at Day 10 (n =9,2,5,3,6,4,4) | 5.2 ± 3.59 | 4.7 ± 6.60 | 7.7 ± 5.36 | 14.3 ± 8.41 | 7.3 ± 10.07 | 11.2 ± 5.14 | 1.4 ± 2.33 |
| QRS Complex: Baseline (n =9,2,5,4,6,5,6) | 96.6 ± 5.83 | 96.0 ± 7.07 | 103.0 ± 9.14 | 101.0 ± 20.05 | 102.7 ± 8.52 | 103.0 ± 8.34 | 95.2 ± 8.70 |
| QRS Complex: Change at Day 10 (n =9,2,5,3,6,4,4) | 0.9 ± 1.60 | -0.5 ± 6.36 | -3.2 ± 9.49 | -2.3 ± 6.17 | 1.3 ± 5.32 | 2.9 ± 5.26 | -1.7 ± 1.83 |
| QT Interval: Baseline (n =9,2,5,4,6,5,6) | 411.9 ± 27.98 | 425.5 ± 10.61 | 407.4 ± 18.17 | 398.0 ± 9.56 | 399.7 ± 16.12 | 397.0 ± 23.29 | 401.8 ± 27.66 |
| QT Interval: Change at Day 10 (n =9,2,5,3,6,4,4) | -3.9 ± 14.72 | 1.0 ± 11.79 | -1.0 ± 23.42 | 2.6 ± 9.26 | 1.3 ± 16.66 | 2.3 ± 5.51 | 2.1 ± 23.19 |
| QTC Interval: Baseline (n =9,2,5,4,6,5,6) | 398.7 ± 11.35 | 415.5 ± 4.95 | 396.4 ± 15.53 | 401.5 ± 15.37 | 396.0 ± 6.54 | 403.2 ± 6.26 | 403.5 ± 11.96 |
| QTC Interval: Change at Day 10 (n =9,2,5,3,6,4,4) | -0.3 ± 9.82 | -1.5 ± 10.14 | -2.9 ± 3.00 | -5.0 ± 10.49 | -1.3 ± 10.34 | -0.3 ± 4.46 | 2.0 ± 10.47 |
| msec | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| PR Interval: Baseline (n =9, 14, 7) | 169.4 ± 15.26 | 156.1 ± 17.78 | 154.7 ± 11.51 |
| PR Interval: Change at Day 28 (n =8, 7, 5) | -0.6 ± 10.19 | 11.1 ± 5.95 | 4.1 ± 7.09 |
| QRS Complex: Baseline (n =9, 14, 7) | 100.6 ± 8.32 | 97.4 ± 10.27 | 93.0 ± 5.87 |
| QRS Complex: Change at Day 28 (n= 8, 7, 5) | 0.5 ± 4.86 | 0.8 ± 4.73 | 3.8 ± 5.26 |
| QT Interval: Baseline (n =9, 14, 7) | 404.4 ± 17.48 | 411.6 ± 31.01 | 379.0 ± 18.94 |
| QT Interval: Change at Day 28 (n =8, 7, 5) | -17.9 ± 16.00 | -22.6 ± 23.04 | -5.3 ± 9.43 |
| QTC Interval: Baseline (n=9, 14, 7) | 409.7 ± 14.46 | 409.0 ± 14.92 | 392.0 ± 19.04 |
| QTC Interval: Change at Day 28 (n= 8, 7, 5) | -8.7 ± 10.83 | -9.6 ± 7.89 | -2.7 ± 13.18 |
| bpm | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline | 56.1 ± 6.83 | 70.3 ± 16.46 | 69.2 ± 12.06 | 55.3 ± 5.65 | 67.7 ± 8.82 | 53.0 ± 8.92 | 58.0 ± 5.17 |
| Change at Day 1 | 2.2 ± 3.74 | 1.6 ± 2.81 | 0.3 ± 3.27 | 4.6 ± 4.64 | -2.3 ± 1.72 | 2.0 ± 3.19 | 3.4 ± 5.79 |
| bpm | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =9, 2, 5, 4, 6, 5, 6) | 55.1 ± 7.15 | 55.5 ± 2.12 | 55.4 ± 4.45 | 61.0 ± 2.94 | 58.5 ± 6.38 | 63.0 ± 7.38 | 61.2 ± 7.96 |
| Change at Day 10 (n = 9, 2, 5, 3, 6, 4, 4) | -1.2 ± 10.33 | 7.7 ± 6.13 | -1.1 ± 7.22 | -3.0 ± 4.04 | -2.3 ± 5.12 | -1.8 ± 5.79 | -1.3 ± 4.04 |
| bpm | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n =9, 14, 7) | 63.1 ± 9.15 | 60.2 ± 11.25 | 66.0 ± 4.93 |
| Change at Day 28 (n =8, 7, 5) | 5.2 ± 5.28 | 4.0 ± 8.73 | 1.4 ± 5.60 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.
| participants | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs | 2 | 1 | 1 | 0 | 1 | 3 | 2 | 0 | 1 | 3 | 2 | 3 | 5 | 5 | 5 | 11 | 6 | 1 | 2 | 0 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrawal due to AEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 | 0 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.
| adverse events | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | 2 | 1 | 1 | 0 | 1 | 4 | 0 | 0 | 1 | 3 | 2 | 2 | 6 | 6 | 7 | 16 | 16 | 1 | 2 | 0 |
| Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(\<) 0.8\*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: \<0.9\*LLN,\>1.1\*upper limit of normal (ULN); platelets: \<0.5\*LLN,\>1.75\*ULN, white blood cell count: \<0.6\*LLN, \>1.5\*ULN; lymphocytes, total neutrophils: \<0.8\*LLN, \>1.2\*ULN; eosinophils, basophils, monocytes: \>1.2\*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: \>1.1\*ULN; liver function: bilirubin: \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\*ULN; protein, albumin: \<0.8\*LLN\>\</0\>1.2\*ULN; renal function:blood urea nitrogen,creatinine: \>1.3\*ULN; uric acid: \>1.2\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\*LLN,\>1.1\*ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\*LLN,\>1.5\*ULN)
| participants | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 7 | 4 | 4 | 6 | 6 | 6 | 7 | 6 | 0 | 5 | 4 | 6 | 5 | 6 | 7 | 13 | 7 | 5 | 1 | 3 |
Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.
| milliliter per minute (mL/min) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline | 117.7 ± 28.70 | 93.0 ± 36.60 | 133.8 ± 29.76 | 95.8 ± 53.07 | 117.0 ± 28.70 | 129.6 ± 25.43 | 114.4 ± 24.64 |
| Change at Day 1 | 24.3 ± 63.75 | -0.4 ± 35.35 | -2.7 ± 11.27 | 15.8 ± 36.79 | -6.4 ± 6.35 | -17.6 ± 28.67 | 73.4 ± 227.50 |
Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.
| mL/min | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n =9, 2, 5, 4, 6, 5, 6, 2, 2, 7) | 114.4 ± 27.75 | 111.0 ± 1.41 | 112.6 ± 42.08 | 115.0 ± 34.13 | 142.5 ± 56.68 | 138.4 ± 51.27 | 83.0 ± 39.73 | 140.5 ± 55.86 | 158.0 ± 36.77 | 172.4 ± 51.74 |
| Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4, 2, 2, 7) | 0.7 ± 33.29 | -2.5 ± 57.28 | 26.8 ± 46.90 | -19.0 ± 25.51 | -47.0 ± 55.68 | -39.5 ± 29.86 | 3.5 ± 40.42 | -38.5 ± 60.10 | -50.0 ± 4.24 | -67.3 ± 61.45 |
Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.
| mL/min | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28 | -10.0 ± 0.0 | -35.0 ± 33.94 | -67.6 ± 50.33 |
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
| nanogram*hour per milliliter (ng*hr/mL) | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|
| Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841 | 6463 ± 46 | 6720 ± 43 | 5321 ± 53 |
Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).
| ng*hr/mL | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|
| Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841 | 6447 ± 46 | 6694 ± 43 | 5305 ± 53 |
| nanogram per milliliter (ng/mL) | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|
| Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 | 1022 ± 35 | 1084 ± 40 | 656.6 ± 26 |
| ng/mL | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 | 5.138 ± 52 | 18.21 ± 92 | 79.30 ± 35 | 271.3 ± 21 | 748.4 ± 35 | 2460 ± 37 | 63.42 ± 11 | 286.6 ± 17 | 734.1 ± 29 | 522.0 ± 31 | 2091 ± 28 | 204.7 ± 43 | 924.2 ± 13 |
| hour | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841 | 1.00 (0.500 to 2.00) | 1.00 (0.500 to 1.00) | 0.500 (0.500 to 1.00) | 1.00 (0.500 to 1.02) | 1.00 (0.500 to 2.00) | 1.00 (0.500 to 2.00) | 1.00 (1.00 to 1.03) | 1.00 (1.00 to 1.00) | 1.50 (1.00 to 2.00) | 1.00 (1.00 to 2.00) | 0.984 (0.500 to 2.00) | 1.00 (0.983 to 1.00) | 2.00 (1.00 to 2.00) |
| hour | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|
| Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841 | 0.500 ± 0.500 | 1.00 ± 1.2965 | 4.00 ± 1.4383 |
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
| ng*hr/mL | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841 | NA ± NA | 145.8 ± 61 | 353.8 ± 31 | 1439 ± 65 | 4797 ± 62 | 18410 ± 46 |
Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.
| ng*hr/mL | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|
| Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841 | 422.8 ± 41 | 1880 ± 52 | 6089 ± 38 | 3560 ± 35 | 16180 ± 15 | 990.0 ± 103 | 7672 ± 43 |
Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).
| ng*hr/mL | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841 | 17.71 ± 114 | 79.18 ± 239 | 340.4 ± 30 | 1431 ± 65 | 5041 ± 59 | 18400 ± 46 |
Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.
| [nanogram/milliliter]/milligram | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841 | 5.138 ± 52 | 6.061 ± 92 | 7.930 ± 35 | 9.033 ± 21 | 7.484 ± 35 | 12.31 ± 37 | 6.342 ± 11 | 9.563 ± 17 | 7.341 ± 29 | 10.43 ± 30 | 11.97 ± 28 | 6.827 ± 43 | 9.242 ± 13 |
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.
| [nanogram*hour/milliliter]/milligram | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841 | NA ± NA | 48.65 ± 61 | 35.38 ± 31 | 47.97 ± 65 | 47.97 ± 62 | 92.13 ± 46 |
Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.
| [ng*hr/mL]/mg | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841 | 17.71 ± 114 | 26.38 ± 239 | 34.04 ± 30 | 47.64 ± 65 | 50.41 ± 59 | 92.09 ± 46 |
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.
| [ng*hr/mL]/mg | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|
| Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841 | 42.28 ± 41 | 62.68 ± 51 | 60.89 ± 38 | 71.15 ± 36 | 92.30 ± 16 |
Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.
| hour | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841 | NA ± NA | 4.554 ± 1.8066 | 3.848 ± 1.1587 | 4.363 ± 2.4126 | 7.519 ± 2.8236 | 6.813 ± 1.9875 | 5.928 ± 3.3336 | 4.860 ± 1.9304 | 10.67 ± 1.8440 | 9.133 ± 2.2579 | 7.458 ± 2.1595 | 16.01 ± 31.584 | 6.032 ± 1.7121 | 6.155 ± 1.4408 | 6.168 ± 1.2965 | 5.848 ± 1.4383 |
MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.
| hour | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841 | NA ± NA | 6.414 ± 46 | 5.169 ± 34 | 5.206 ± 44 | 7.277 ± 37 | 8.758 ± 29 | 7.191 ± 45 | 6.830 ± 38 | 10.35 ± 25 | 9.592 ± 22 | 9.025 ± 26 | 6.072 ± 92 | 8.534 ± 36 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| liter | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841 | NA ± NA | 126.4 ± 26 | 151.0 ± 18 | 115.7 ± 16 | 210.5 ± 45 | 102.4 ± 27 | 177.6 ± 30 | 106.2 ± 12 | 249.4 ± 45 | 180.9 ± 30 | 112.4 ± 18 | 245.4 ± 206 | 109.6 ± 18 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.
| Liter per hour (L/hr) | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841 | NA ± NA | 20.57 ± 61 | 28.26 ± 31 | 20.82 ± 65 | 20.85 ± 61 | 10.86 ± 46 | 23.65 ± 41 | 15.95 ± 51 | 16.43 ± 38 | 14.03 ± 35 | 10.83 ± 16 | 30.30 ± 103 | 13.04 ± 43 |
PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC\[tau\]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.
| ratio | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|---|---|---|---|
| Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841 | 2.815 ± 40 | 3.543 ± 38 | 2.643 ± 31 | 1.297 ± 22 | 2.911 ± 43 | 3.414 ± 44 | 2.654 ± 42 |
Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.
| milligram | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|
| Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau) | 1.109 ± 45 | 2.798 ± 57 | NA ± NA | 7.758 ± 57 | 15.60 ± 44 |
Aetau% was calculated as: 100\*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.
| percentage of dose recovered | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|
| Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%) | 11.09 ± 45 | 9.332 ± 57 | NA ± NA | 15.54 ± 57 | 8.910 ± 44 |
Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.
| Liter per hour | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|
| Multiple Ascending Dose (MAD) Cohort: Renal Clearance | 2.619 ± 18 | 1.486 ± 15 | NA ± NA | 2.179 ± 31 | 0.9629 ± 58 |
Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.
| picogram per milliliter (pg/mL) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline | 119.17 ± 40.090 | 188.76 ± 238.380 | 219.62 ± 275.440 | 78.28 ± 29.481 | 141.38 ± 100.403 | 115.00 ± 38.458 | 114.33 ± 26.164 |
Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.
| pg/mL | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =9, 2, 5, 4, 6, 5, 6) | 114.04 ± 70.658 | 85.50 ± 13.011 | 101.12 ± 56.853 | 142.23 ± 165.924 | 106.43 ± 28.244 | 121.60 ± 20.959 | 135.42 ± 57.855 |
| Change at Day 2 (n =9, 2, 5, 4, 6, 5, 6) | 5.66 ± 13.421 | 2.00 ± 13.294 | -20.14 ± 41.966 | -23.60 ± 82.888 | -47.52 ± 19.664 | -60.64 ± 16.913 | -67.73 ± 35.998 |
| Change at Day 5 (n =9, 2, 5, 4, 6, 5, 6) | 4.33 ± 12.213 | -3.25 ± 13.506 | -42.12 ± 48.250 | -53.40 ± 125.815 | -55.80 ± 15.273 | -71.40 ± 11.857 | -80.65 ± 66.445 |
| Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4) | -1.92 ± 24.123 | 4.75 ± 9.687 | -40.10 ± 43.129 | -96.67 ± 134.176 | -57.22 ± 9.321 | -70.50 ± 14.007 | -106.40 ± 60.163 |
| Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4) | 11.01 ± 19.008 | 1.85 ± 0.778 | -37.56 ± 47.031 | -102.53 ± 131.223 | -37.95 ± 24.957 | -54.25 ± 23.972 | -112.20 ± 60.459 |
| Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4) | -14.59 ± 21.736 | 2.85 ± 11.102 | -11.76 ± 51.955 | -62.07 ± 94.378 | 8.48 ± 23.010 | 18.30 ± 34.748 | -47.15 ± 89.356 |
Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.
| pg/mL | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n =9, 14, 7) | 302.00 ± 281.552 | 127.58 ± 45.829 | 123.09 ± 22.244 |
| Change at Day 2 (n =9, 14, 7) | 53.44 ± 214.334 | -8.51 ± 34.704 | -49.57 ± 35.759 |
| Change at Day 5 (n =9, 14, 7) | -21.63 ± 142.195 | -33.93 ± 33.465 | -49.01 ± 35.998 |
| Change at Day 7 (n =9, 12, 7) | -25.71 ± 133.510 | -31.31 ± 32.203 | -52.50 ± 42.216 |
| Change at Day 14 (n =9, 10, 6) | -69.91 ± 106.951 | -52.06 ± 24.663 | -68.55 ± 28.524 |
| Change at Day 21 (n =9, 9, 5) | -42.87 ± 122.986 | -51.47 ± 28.094 | -46.64 ± 27.340 |
| Change at Day 28 (n =8, 7, 5) | -1.0 ± 31.351 | -46.19 ± 35.893 | -53.36 ± 19.771 |
| Change at Day 29 (n =8, 7, 5) | -22.20 ± 95.930 | -37.50 ± 31.849 | -49.34 ± 14.306 |
| Change at Day 35 (n =8, 6, 5) | -69.54 ± 124.165 | 10.45 ± 37.860 | 110.68 ± 108.041 |
| Change at Day 56 (n =7, 6, 4) | -31.71 ± 67.158 | 16.18 ± 19.348 | 167.85 ± 201.780 |
Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.
| milligram per deciliter (mg/dL) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline | 0.1220 ± 0.11909 | 0.1066 ± 0.09662 | 0.6420 ± 1.41413 | 0.0757 ± 0.04523 | 0.2290 ± 0.11714 | 0.1158 ± 0.20871 | 0.1710 ± 0.10387 |
Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.
| mg/dL | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n= 9, 2, 5, 4, 6, 5, 6) | 0.0974 ± 0.06791 | 0.0815 ± 0.08556 | 0.1002 ± 0.11675 | 0.0983 ± 0.03734 | 0.0505 ± 0.02799 | 0.0746 ± 0.02523 | 0.1902 ± 0.06394 |
| Change at Day 2 (n= 9, 2, 5, 4, 6, 5, 6) | -0.0148 ± 0.03176 | -0.0205 ± 0.00071 | -0.0670 ± 0.08196 | -0.0408 ± 0.03052 | -0.0212 ± 0.01712 | -0.0298 ± 0.01743 | -0.0307 ± 0.08168 |
| Change at Day 5 (n= 9, 2, 5, 4, 6, 5, 6) | -0.0352 ± 0.03847 | -0.0050 ± 0.02263 | -0.0972 ± 0.11656 | -0.0753 ± 0.02269 | -0.0435 ± 0.02202 | -0.0596 ± 0.03345 | -0.1078 ± 0.05948 |
| Change at Day 10 (n= 9, 2, 5, 3, 6, 4, 4) | -0.0329 ± 0.05656 | 0.0015 ± 0.00778 | -0.1002 ± 0.11675 | -0.0903 ± 0.00961 | -0.0467 ± 0.02881 | -0.0618 ± 0.01445 | -0.1838 ± 0.04529 |
| Change at Day 11 (n= 9, 2, 5, 3, 6, 4, 4) | -0.0186 ± 0.07315 | -0.0040 ± 0.00990 | -0.1002 ± 0.11675 | -0.0870 ± 0.00819 | -0.0435 ± 0.02849 | -0.0615 ± 0.01330 | -0.1878 ± 0.04136 |
| Change at Day 28 (n= 9, 2, 5, 3, 6, 4, 4) | 0.0496 ± 0.18748 | 0.0790 ± 0.08910 | -0.0352 ± 0.15033 | 0.0023 ± 0.06001 | 0.0223 ± 0.01556 | -0.0275 ± 0.04086 | 1.1255 ± 1.63253 |
Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.
| mg/dL | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n =9, 14, 7) | 1.0699 ± 1.39179 | 0.5694 ± 1.11752 | 0.3143 ± 0.34167 |
| Change at Day 2 (n =9, 14, 7) | -0.1096 ± 0.25370 | -0.3408 ± 0.86901 | -0.0189 ± 0.14180 |
| Change at Day 5 (n =9, 14, 7) | 0.0204 ± 0.51424 | -0.2413 ± 1.45363 | -0.2119 ± 0.27245 |
| Change at Day 7 (n =9, 12, 7) | 0.1958 ± 0.85725 | -0.1573 ± 1.90640 | -0.1983 ± 0.31021 |
| Change at Day 14 (n =9, 10, 6) | 0.4118 ± 1.19190 | -0.1910 ± 0.65215 | -0.2582 ± 0.33762 |
| Change at Day 21 (n =9, 9, 5) | -0.1397 ± 0.46958 | -0.3067 ± 0.61035 | -0.2716 ± 0.38954 |
| Change at Day 28 (n =8, 7, 5) | -0.4075 ± 0.37814 | -0.3549 ± 0.69576 | -0.2670 ± 0.37674 |
| Change at Day 29 (n =8, 7, 5) | -0.6113 ± 0.79373 | -0.3533 ± 0.69589 | -0.2626 ± 0.34387 |
| Change at Day 35 (n =8, 6, 5) | -0.5945 ± 0.78042 | -0.2533 ± 0.79446 | 0.7546 ± 1.07215 |
| Change at Day 56 (n =7, 6, 4) | -0.3407 ± 0.45280 | -0.2662 ± 0.78307 | 0.2533 ± 0.82107 |
| cells per millimeter cube (cells/mm^3) | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =13, 7, 6, 6, 6, 8, 8) | 2.988 ± 1.2090 | 2.433 ± 1.0574 | 3.097 ± 1.1903 | 2.500 ± 0.6782 | 3.048 ± 0.7552 | 2.973 ± 1.2374 | 2.858 ± 0.6901 |
| Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8) | 0.096 ± 0.7459 | 0.340 ± 0.6643 | 0.377 ± 0.7133 | 0.285 ± 0.3214 | 0.240 ± 0.7344 | -0.315 ± 0.8594 | -0.760 ± 0.5266 |
| Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8) | 0.047 ± 0.8048 | 0.280 ± 0.5187 | -0.162 ± 1.1032 | -0.170 ± 0.2265 | -0.170 ± 0.6963 | 0.296 ± 0.3849 | 0.654 ± 0.6930 |
| Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8) | -0.245 ± 0.7834 | 0.196 ± 0.1674 | 0.017 ± 1.1173 | -0.293 ± 0.3100 | -0.058 ± 0.9051 | -0.110 ± 0.7910 | 1.188 ± 1.8134 |
| cells/mm^3 | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =9, 2, 5, 4, 6, 5, 6) | 2.584 ± 0.8858 | 2.340 ± 0.2970 | 2.676 ± 0.6726 | 2.770 ± 0.4907 | 2.710 ± 1.0372 | 2.690 ± 0.9337 | 3.217 ± 0.9677 |
| Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6) | 0.099 ± 0.4191 | 0.060 ± 0.0283 | -0.242 ± 1.1533 | -0.215 ± 0.6376 | -0.295 ± 0.8000 | -0.980 ± 0.3726 | -0.902 ± 2.0680 |
| Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5) | 0.239 ± 0.5725 | 0.635 ± 1.1526 | -0.296 ± 0.7032 | -0.178 ± 0.5160 | -0.793 ± 0.5720 | -0.913 ± 0.4039 | -1.702 ± 1.3292 |
| Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4) | 0.156 ± 0.5860 | 0.635 ± 1.0394 | -0.340 ± 0.8602 | 0.327 ± 0.8228 | -1.012 ± 0.5365 | -1.168 ± 0.4197 | -2.125 ± 1.2878 |
| Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4) | 0.158 ± 0.4996 | 0.400 ± 1.2021 | -0.382 ± 0.8244 | 0.260 ± 0.7572 | -0.280 ± 0.9159 | -0.248 ± 0.3976 | -2.010 ± 1.3075 |
| Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4) | -0.020 ± 0.5471 | 0.385 ± 0.8273 | -0.060 ± 0.8663 | 0.650 ± 0.8543 | 0.232 ± 0.4395 | 0.228 ± 0.3377 | 0.290 ± 1.0943 |
| Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4) | 0.030 ± 0.4649 | 0.130 ± 0.4525 | -0.012 ± 1.1401 | 0.697 ± 0.0839 | -0.055 ± 0.4578 | 0.050 ± 0.6249 | 0.298 ± 0.3777 |
| cells/mm^3 | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n =9, 14, 7) | 4.109 ± 1.4401 | 3.640 ± 1.4997 | 3.909 ± 1.1841 |
| Change at Day 4 (n =9, 14, 7) | -0.402 ± 0.9308 | 0.006 ± 1.1696 | 0.153 ± 0.7114 |
| Change at Day 6 (n =9, 14, 7) | -0.209 ± 1.2224 | -0.073 ± 0.8229 | -0.303 ± 0.6058 |
| Change at Day 8 (n =9, 12, 7) | -0.473 ± 0.6962 | 0.013 ± 1.2572 | -0.973 ± 0.4394 |
| Change at Day 10 (n =9, 10, 7) | -0.463 ± 0.7834 | 0.197 ± 1.1099 | -1.299 ± 0.6906 |
| Change at Day 13 (n =9, 10, 6) | -0.654 ± 0.7847 | -0.297 ± 1.2264 | -1.538 ± 0.9097 |
| Change at Day 14 (n =9, 10, 6) | -0.247 ± 0.9682 | -0.146 ± 1.1226 | -1.465 ± 0.9517 |
| Change at Day 21 (n =9, 9, 5) | -0.762 ± 0.7389 | -0.638 ± 0.9404 | -1.410 ± 1.2572 |
| Change at Day 28 (n =8, 7, 5) | -0.678 ± 0.6416 | -0.890 ± 0.9952 | -1.450 ± 1.1195 |
| Change at Day 35 (n =8, 6, 5) | -0.081 ± 1.4496 | -0.777 ± 1.1154 | -1.008 ± 0.8082 |
| Change at Day 42 (n =7, 6, 4) | -0.427 ± 0.6004 | -0.677 ± 1.1209 | -1.050 ± 0.6868 |
| Change at Day 56 (n =7, 6, 4) | -0.036 ± 0.7864 | -0.533 ± 1.3025 | -0.493 ± 1.6373 |
| cells/mm^3 | Placebo: SAD Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 200 mg SAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =13, 7, 6, 6, 6, 8, 8) | 1.23 ± 0.470 | 1.19 ± 0.380 | 0.98 ± 0.279 | 1.25 ± 0.243 | 1.25 ± 0.327 | 1.44 ± 0.825 | 1.20 ± 0.524 |
| Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8) | 0.02 ± 0.152 | -0.09 ± 0.135 | -0.02 ± 0.160 | -0.15 ± 0.138 | 0.02 ± 0.256 | -0.14 ± 0.177 | -0.16 ± 0.177 |
| Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8) | 0.04 ± 0.194 | 0.07 ± 0.175 | -0.05 ± 0.138 | -0.27 ± 0.103 | 0.02 ± 0.409 | -0.23 ± 0.459 | -0.15 ± 0.193 |
| Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8) | 0.03 ± 0.234 | 0.04 ± 0.114 | 0.03 ± 0.242 | -0.15 ± 0.226 | 0.34 ± 0.532 | -0.26 ± 0.478 | -0.14 ± 0.346 |
| cells/mm^3 | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort |
|---|---|---|---|---|---|---|---|
| Baseline (n =9, 2, 5, 4, 6, 5, 6) | 1.26 ± 0.490 | 0.85 ± 0.212 | 1.22 ± 0.363 | 1.03 ± 0.350 | 1.40 ± 0.410 | 2.26 ± 0.550 | 1.38 ± 0.286 |
| Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6) | -0.03 ± 0.212 | 0.05 ± 0.071 | -0.10 ± 0.071 | 0.05 ± 0.129 | -0.18 ± 0.306 | -0.54 ± 0.241 | -0.32 ± 0.223 |
| Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5) | -0.11 ± 0.285 | 0.30 ± 0.283 | -0.20 ± 0.100 | -0.13 ± 0.250 | -0.60 ± 0.210 | -1.28 ± 0.395 | -0.90 ± 0.187 |
| Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4) | -0.19 ± 0.398 | 0.20 ± 0.283 | -0.24 ± 0.089 | -0.07 ± 0.231 | -0.70 ± 0.352 | -1.48 ± 0.403 | -0.93 ± 0.206 |
| Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4) | -0.13 ± 0.343 | 0.30 ± 0.424 | -0.34 ± 0.089 | -0.23 ± 0.115 | -0.72 ± 0.354 | -1.43 ± 0.499 | -0.93 ± 0.330 |
| Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4) | -0.12 ± 0.393 | 0.05 ± 0.495 | -0.22 ± 0.110 | 0.03 ± 0.058 | -0.60 ± 0.297 | -1.10 ± 0.408 | -0.90 ± 0.183 |
| Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4) | 0.11 ± 0.431 | -0.05 ± 0.212 | 0.22 ± 0.277 | 0.30 ± 0.346 | 0.65 ± 0.619 | 0.18 ± 0.189 | 0.33 ± 0.479 |
| cells/mm^3 | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort |
|---|---|---|---|
| Baseline (n =9, 14, 7) | 1.49 ± 0.355 | 1.45 ± 0.285 | 1.31 ± 0.393 |
| Change at Day 4 (n =9, 14, 7) | -0.10 ± 0.300 | -0.09 ± 0.207 | -0.13 ± 0.281 |
| Change at Day 6 (n =9, 14, 7) | -0.09 ± 0.392 | -0.16 ± 0.250 | -0.27 ± 0.373 |
| Change at Day 8 (n =9, 12, 7) | -0.20 ± 0.430 | -0.21 ± 0.243 | -0.59 ± 0.353 |
| Change at Day 10 (n =9, 10, 7) | -0.21 ± 0.355 | -0.35 ± 0.295 | -0.70 ± 0.361 |
| Change at Day 13 (n =9, 10, 6) | -0.20 ± 0.354 | -0.41 ± 0.373 | -0.75 ± 0.459 |
| Change at Day 14 (n =9, 10, 6) | -0.13 ± 0.371 | -0.34 ± 0.392 | -0.82 ± 0.462 |
| Change at Day 21 (n =9, 9, 5) | -0.22 ± 0.393 | -0.27 ± 0.430 | -0.66 ± 0.270 |
| Change at Day 28 (n =8, 7, 5) | -0.24 ± 0.487 | -0.36 ± 0.264 | -0.60 ± 0.255 |
| Change at Day 35 (n =8, 6, 5) | 0.26 ± 0.498 | -0.03 ± 0.163 | 0.22 ± 0.228 |
| Change at Day 42 (n =7, 6, 4) | 0.46 ± 0.431 | 0.33 ± 0.427 | 1.35 ± 0.551 |
| Change at Day 56 (n =7, 6, 4 | 0.13 ± 0.335 | 0.07 ± 0.250 | 0.50 ± 0.183 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: SAD Cohort | — | 0/13 (0%) | 2/13 (15.4%) |
| Placebo: Once Daily MAD Cohort | — | 0/9 (0%) | 0/9 (0%) |
| Placebo: Twice Daily MAD Cohort | — | 0/2 (0%) | 1/2 (50%) |
| Placebo: MAD Psoriasis Cohort | — | 0/9 (0%) | 5/9 (55.6%) |
| PF--06700841: 1 Milligram (mg) SAD Cohort | — | 0/7 (0%) | 1/7 (14.3%) |
| PF--06700841: 3 mg SAD Cohort | — | 0/6 (0%) | 1/6 (16.7%) |
| PF-06700841: 10 mg SAD Cohort | — | 0/6 (0%) | 0/6 (0%) |
| PF-06700841: 10 mg Once Daily MAD Cohort | — | 0/5 (0%) | 3/5 (60%) |
| PF-06700841: 30 mg SAD Cohort | — | 0/6 (0%) | 1/6 (16.7%) |
| PF-06700841: 30 mg Once Daily MAD Cohort | — | 0/4 (0%) | 2/4 (50%) |
| PF-06700841: 100 mg SAD Cohort | — | 0/8 (0%) | 3/8 (37.5%) |
| PF-06700841: 100 mg Once Daily MAD Cohort | — | 0/6 (0%) | 3/6 (50%) |
| PF-06700841: 50 mg Twice Daily MAD Cohort | — | 0/5 (0%) | 5/5 (100%) |
| PF-06700841: 200 mg SAD Cohort | — | 0/8 (0%) | 2/8 (25%) |
| PF-06700841: 175 mg Once Daily MAD Cohort | — | 0/6 (0%) | 5/6 (83.3%) |
| PF-06700841: 30 mg MAD Psoriasis Cohort | — | 0/14 (0%) | 11/14 (78.6%) |
| PF-06700841: 100 mg MAD Psoriasis Cohort | — | 0/7 (0%) | 6/7 (85.7%) |
| PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | — | 0/12 (0%) | 1/12 (8.3%) |
| PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | — | 0/12 (0%) | 2/12 (16.7%) |
| PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) | — | 0/12 (0%) | 0/12 (0%) |
| Event | Placebo: SAD Cohort | Placebo: Once Daily MAD Cohort | Placebo: Twice Daily MAD Cohort | Placebo: MAD Psoriasis Cohort | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF-06700841: 10 mg SAD Cohort | PF-06700841: 10 mg Once Daily MAD Cohort | PF-06700841: 30 mg SAD Cohort | PF-06700841: 30 mg Once Daily MAD Cohort | PF-06700841: 100 mg SAD Cohort | PF-06700841: 100 mg Once Daily MAD Cohort | PF-06700841: 50 mg Twice Daily MAD Cohort | PF-06700841: 200 mg SAD Cohort | PF-06700841: 175 mg Once Daily MAD Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Tab Fasted (Food Effect Cohort) | PF-06700841: 100 mg Solution Fasted (Food Effect Cohort) | PF-06700841: 100 mg Tablet Fed (Food Effect Cohort) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood creatinine increasedInvestigations | 0/13 | 0/9 | 0/2 | 1/9 | 0/7 | 0/6 | 0/6 | 1/5 | 0/6 | 1/4 | 1/8 | 1/6 | 4/5 | 1/8 | 4/6 | 7/14 | 6/7 | 0/12 | 0/12 | 0/12 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/13 | 0/9 | 1/2 | 0/9 | 0/7 | 0/6 | 0/6 | 0/5 | 0/6 | 0/4 | 0/8 | 0/6 | 0/5 | 0/8 | 0/6 | 0/14 | 1/7 | 0/12 | 0/12 | 0/12 |
| Neutrophil count decreasedInvestigations | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 0/6 | 0/6 | 0/5 | 0/6 | 0/4 | 0/8 | 0/6 | 2/5 | 0/8 | 1/6 | 1/14 | 1/7 | 0/12 | 0/12 | 0/12 |
| ConstipationGastrointestinal disorders | 0/13 | 0/9 | 0/2 | 3/9 | 0/7 | 0/6 | 0/6 | 0/5 | 0/6 | 0/4 | 1/8 | 0/6 | 0/5 | 0/8 | 1/6 | 3/14 | 0/7 | 0/12 | 0/12 | 0/12 |
| PresyncopeNervous system disorders | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 0/6 | 0/6 | 0/5 | 0/6 | 1/4 | 1/8 | 0/6 | 0/5 | 0/8 | 0/6 | 0/14 | 0/7 | 0/12 | 0/12 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 0/6 | 0/6 | 1/5 | 0/6 | 0/4 | 0/8 | 1/6 | 0/5 | 0/8 | 0/6 | 0/14 | 1/7 | 0/12 | 0/12 | 0/12 |
| SyncopeNervous system disorders | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 0/6 | 0/6 | 1/5 | 0/6 | 0/4 | 0/8 | 0/6 | 0/5 | 0/8 | 0/6 | 0/14 | 0/7 | 0/12 | 0/12 | 0/12 |
| NeutropeniaBlood and lymphatic system disorders | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 0/6 | 0/6 | 0/5 | 0/6 | 0/4 | 0/8 | 0/6 | 0/5 | 0/8 | 1/6 | 0/14 | 0/7 | 0/12 | 0/12 | 0/12 |
| HeadacheNervous system disorders | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 1/6 | 0/6 | 0/5 | 0/6 | 0/4 | 0/8 | 1/6 | 0/5 | 1/8 | 0/6 | 1/14 | 1/7 | 0/12 | 1/12 | 0/12 |
| HaematomaVascular disorders | 0/13 | 0/9 | 0/2 | 0/9 | 0/7 | 0/6 | 0/6 | 0/5 | 1/6 | 0/4 | 0/8 | 0/6 | 0/5 | 0/8 | 0/6 | 0/14 | 0/7 | 0/12 | 0/12 | 0/12 |
| Age, Customized(participants) | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Food Effect Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-44 Years | 4 | 2 | 1 | 4 | 5 | 6 | 11 | 6 | 6 | 5 | 5 | 55 |
| 45-64 Years | 3 | 4 | 5 | 2 | 3 | 2 | 2 | 3 | 8 | 2 | 7 | 41 |
| Gender(Participants) | PF--06700841: 1 Milligram (mg) SAD Cohort | PF--06700841: 3 mg SAD Cohort | PF--06700841: 10 mg SAD Cohort Then MAD Cohort | PF-06700841: 30 mg SAD Cohort Then MAD Cohort | PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort | PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort | Placebo: SAD Cohort Then MAD Cohort | Placebo: MAD Psoriasis Cohort | PF-06700841: 30 mg MAD Psoriasis Cohort | PF-06700841: 100 mg MAD Psoriasis Cohort | PF-06700841: 100 mg Food Effect Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 6 |
| Male | 7 | 6 | 6 | 6 | 8 | 7 | 12 | 8 | 12 | 7 | 11 | 90 |
The record gives a start of Nov 2014, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841